SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Drug discovery management, small is still beautiful: Why a number of companies get it wrong
9 references·2 citing·41 second hop
Drug discovery management, small is still beautiful: Why a number of companies get it wrong (2011)Drug discovery management, small is still…Clusters and the New Economics of Competition (2014)Clusters and the New Economic…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…Lessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Rebuilding the R&D engine in big pharma. (2008)Rebuilding the R&D engine in …Drug discovery in jeopardy (2006)Drug discovery in jeopardyA Personal Perspective on Dr. Paul Janssen (2005)A Personal Perspective on Dr.…Cutting the cost of drug development? (2004)Cutting the cost of drug deve…Strategic trends in the drug industry (2003)Strategic trends in the drug …The power of ethical management (1988)The power of ethical manageme…“Collaborative Innovation”—Regaining the Edge in Drug Discovery (2013)“Collaborative Innovation”—Re…Drug discovery in the next decade: innovation needed ASAP (2011)Drug discovery in the next de…Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The price of innovation: new estimates of drug development costs (2003)The black swan: the impact of the highly improbable (2007)The productivity crisis in pharmaceutical R&D (2011)THE WORLD MEDICINES SITUATION 2011 (2011)Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)Returns to R&D on new drug introductions in the 1980s (1994)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)Making a difference: 30 years of TDR (2008)The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies (2011)The risks of risk aversion in drug regulation (2013)The Structure of Scientific Revolutions (1963)Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries (2013)Restoring the pharmaceutical industry's reputation (2014)Corporate Investment Relationships and the Search for Innovations: An Examination of Startups’ Search Shift Toward Incumbents (2021)Prospects for productivity (2004)US academic drug discovery (2011)Translational research: the changing landscape of drug discovery (2012)Racing to define pharmaceutical R&D external innovation models (2014)Blue ocean strategy : how to create uncontested market space and make the competition irrelevant (2005)Quality assurance mechanisms for the unregulated research environment (2013)Entrepreneurial patent management in pharmaceutical startups (2016)Measuring the effectiveness and impact of an open innovation platform (2017)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Can the pharmaceutical industry reduce attrition rates? (2004)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)The impact of mergers on pharmaceutical R&D (2011)Big Pharma, little science? (2012)Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry (2018)Excellence V. Effectiveness: Macintyre’s Critique of Business (1995)The Hierarchical Abuse of Power in Work Organizations (1998)Ethical Leadership (2010)Successful pharmaceutical discovery: Paul Janssen's concept of drug research (2007)The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice (2009)The fall and rise of pharmacology – (Re-)defining the discipline? (2013)Chapter 49 Evidence on the nature and sources of agglomeration economies (2004)Clusters and knowledge: local buzz, global pipelines and the process of knowledge creation (2004)Cities and the Creative Class (2005)
this work references cited by second hop

References

  • 2014Clusters and the New Economics of Competition4,810 cited
  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
  • 2009Lessons from 60 years of pharmaceutical innovation1,207 cited
  • 2008Rebuilding the R&D engine in big pharma.230 cited
  • 2006Drug discovery in jeopardy209 cited
  • 2004Cutting the cost of drug development?187 cited
  • 2003Strategic trends in the drug industry165 cited
  • 1988The power of ethical management159 cited
  • 2005A Personal Perspective on Dr. Paul Janssen41 cited

Cited by

  • 2011Drug discovery in the next decade: innovation needed ASAP117 cited
  • 2013“Collaborative Innovation”—Regaining the Edge in Drug Discovery9 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work